Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Guardian Technologies International has announced a collaboration agreement to further validate the real world application of Signature Mapping(TM) and to develop a prototype that will serve as a model for future use by radiologists. Guardian Technologies International, Inc., provider of medical imaging and threat detection technology, announced that the Medical Imaging and Informatics Laboratory at the University of California (USC) has extended its collaboration agreement with the company to further validate the real world application of Signature Mapping(TM) and to develop a prototype that will serve as a model for future use by radiologists.

Clinical evaluation and initial prototype development will be led by Dr. H.K. Huang, Professor of Radiology and Biomedical Engineering at USC. Dr. Huang and his team will be evaluating feedback provided by radiologists regarding potential enhancements to Signature Mapping visualization tools and integration methodology as it applies to medical radiological imaging workflow.

"We believe that working with Dr. Huang and his world-class team at USC provides further validation for Signature Mapping and takes us one step closer to delivering the promise of our technology to radiologists around the world," said Bill Donovan, President and Chief Operating Officer of Guardian Technologies International. "This agreement is yet another example of Guardian's continued mission to commercialize Signature Mapping as a primary means of building exceptional value for our shareholders."

According to the agreement, Guardian and USC will collaborate on three distinct areas: breast imaging and breast cancer research; chest imaging and tuberculosis detection and monitoring; and traumatic brain injury and acute intracranial brain hemorrhaging.

Focusing on breast imaging and breast cancer detection, USC will provide continued analytical validation of Signature Mapping as it relates to the recently announced success from the South Florida mammography database. USC will also focus on the development and evaluation of a clinical prototype for use in mammography for the visualization of breast cancer and study the integrated use of MRI and mammography as an effective screening and diagnostic tool.

USC will also support the development and evaluation of a prototype for use in screening, monitoring and staging after the detection of tuberculosis. USC's clinical focus will be on chest x-rays, either from direct digital or scanned film.

Furthermore, USC will apply its efforts towards Signature Mapping's application to acute traumatic brain injury with the development and evaluation of a prototype for use in detection and quantification of acute intracranial hemorrhage, with primary deployment on CT scanners. USC will also assess how the current work in multiple sclerosis and normal pressure hydrocephalus can be used for patient screening and evaluation in traumatic brain injury work that was jointly conducted last year.

Signature Mapping is protected by a robust patent portfolio. Guardian has already undertaken research, development and clinical evaluation on challenges ranging from more precise and earlier detection of breast and prostate cancer. Research has also proven that Signature Mapping can automatically detect intracranial hemorrhagic associated with traumatic brain injuries using CTs, and can locate and quantify multiple sclerosis lesions in MRIs, as well as the extent of tuberculosis, pneumoconiosis, and even cancer in the lungs using commonly available and inexpensive chest x-rays.